secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001193125-25-122076
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction
--------------------------------------------------------------------------------

- Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.
- 14 of 18 patients showed clinically meaningful improvement (≥4 points) on mNIS+7 at 24 months.
- 5 of 6 patients previously on patisiran and progressing achieved improvement on mNIS+7 at 24 months.
- Enrollment progressing well in Phase 3 MAGNITUDE-2 trial for ATTRv-PN; potential BLA submission by 2028.
- No new drug-related adverse events; most common were mild-to-moderate infusion reactions with no discontinuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/0001193125-25-122076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525122076/d80735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer